Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Biological Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 17548355
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BRAIN RES BULL

  2008cited by this paper
• Dysfunction of amyloid precursor protein signaling in neurons leads to DNA synthesis and apoptosis.

  2007cited by this paper
• The Tottori (D7N) and English (H6R) Familial Alzheimer Disease Mutations Accelerate Aβ Fibril Formation without Increasing Protofibril Formation*

  2007cited by this paper
• Abeta40 inhibits amyloid deposition in vivo.

  2007cited by this paper
• Reduction in Mitochondrial Superoxide Dismutase Modulates Alzheimer's Disease-Like Pathology and Accelerates the Onset of Behavioral Changes in Human Amyloid Precursor Protein Transgenic Mice

  2006cited by this paper
• A specific amyloid-beta protein assembly in the brain impairs memory.

  2006cited by this paper
• Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt.

  2006cited by this paper
• The amyloid precursor protein: beyond amyloid

  2006cited by this paper
• Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration.

  2006cited by this paper
• Current pharmacotherapy for Alzheimer's disease.

  2006cited by this paper
• Progressive neuronal loss and behavioral impairments of transgenic C57BL/6 inbred mice expressing the carboxy terminus of amyloid precursor protein.

  2006cited by this paper
• Correction for Galvan et al., Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664

  2006cited by this paper
• Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications.

  2006cited by this paper
• Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Cytoplasmic domain of the β‐amyloid protein precursor of Alzheimer's disease: Function, regulation of proteolysis, and implications for drug development

  2005cited by this paper
• Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory

  2005cited by this paper
• Vulnerability of Dentate Granule Cells to Disruption of Arc Expression in Human Amyloid Precursor Protein Transgenic Mice

  2005cited by this paper
• High beta-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-beta levels: implications for the treatment of Alzheimer disease.

  2005cited by this paper
• Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

  2005cited by this paper
• Global prevalence of dementia: a Delphi consensus study

  2005cited by this paper
• Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration.

  2005cited by this paper
• Behavioral phenotypes of amyloid‐based genetically modified mouse models of Alzheimer's disease

  2005cited by this paper
• Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

  2005cited by this paper
• Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches

  2004cited by this paper
• Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy.

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques.

  2004cited by this paper
• Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5

  2004cited by this paper
• Deciphering the molecular basis of memory failure in Alzheimer's disease.

  2004cited by this paper
• Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation

  2004cited by this paper
• In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins.

  2004cited by this paper
• Soluble Arctic amyloid β protein inhibits hippocampal long‐term potentiation in vivo

  2004cited by this paper
• Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice

  2004cited by this paper
• ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

  2004cited by this paper
• Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores.

  2003cited by this paper
• Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease.

  2003cited by this paper
• Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta.

  2003cited by this paper
• Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits

  2003cited by this paper
• Alzheimer disease in the US population: prevalence estimates using the 2000 census.

  2003cited by this paper
• Rationalization of the effects of mutations on peptide andprotein aggregation rates

  2003cited by this paper
• Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.

  2002cited by this paper
• Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability*

  2002cited by this paper
• The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

  2002cited by this paper
• Neurodegenerative disease: Amyloid pores from pathogenic mutations

  2002cited by this paper
• TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice.

  2001cited by this paper
• The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.

  2001cited by this paper
• Measuring normal and pathological anxiety-like behaviour in mice: a review.

  2001cited by this paper
• Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

  2001cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000cited by this paper
• Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice.

  2000cited by this paper
• The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.

  2000cited by this paper
• In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation.

  1999cited by this paper
• Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.

  1999cited by this paper
• Manipulating the Amyloid-β Aggregation Pathway with Chemical Chaperones*

  1999cited by this paper
• Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons

  1999cited by this paper
• Behavioral Changes in Transgenic Mice Expressing Both Amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Association with Amyloid Deposits

  1999cited by this paper
• Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

  1998cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• Abeta associated neuropil changes: correlation with neuronal loss and dementia.

  1998cited by this paper
• Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

  1997cited by this paper
• Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

  1996cited by this paper
• Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease*

  1996cited by this paper
• Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*)

  1995cited by this paper
• Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins.

  1995cited by this paper
• Evidence that A beta 42 is the real culprit in Alzheimer's disease.

  1995cited by this paper
• Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths.

  1994cited by this paper
• Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.

  1992cited by this paper
• Behavioral correlates of denervation and reinnervation of the hippocampal formation of the rat: open field activity and cue utilization following bilateral entorhinal cortex lesions.

  1977cited by this paper

• HCN2 deficiency correlates with memory deficits and hyperexcitability of dCA1 pyramidal neurons in Alzheimer’s disease

  2025cites this paper
• FGFR1 agonists alleviate pathology and cognitive impairment in an Alzheimer's disease mouse model.

  2025cites this paper
• Presenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer's Disease.

  2025cites this paper
• Low-intensity pulsed ultrasound enhances microglial-mediated Aβ clearance and synaptic preservation in an APP transgenic mouse model of Alzheimer's disease.

  2025cites this paper
• Remote spatial memory deficits in mouse models of neuropsychiatric disorders with immature dentate gyrus phenotype

  2025cites this paper
• Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease

  2025cites this paper
• ALZ‐801 prevents amyloid β‐protein assembly and reduces cytotoxicity: A preclinical experimental study

  2025cites this paper
• An aminosterol breaks the autocatalytic cycle of Aβ42 aggregation and protects cell membranes from its soluble aggregates

  2025cites this paper
• Aβ∗56 is a stable oligomer that impairs memory function in mice

  2024cites this paper
• Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.

  2024cites this paper
• The deficient CLEC5A ameliorates the behavioral and pathological deficits via the microglial Aβ clearance in Alzheimer’s disease mouse model

  2024cites this paper
• The duality of amyloid-β: its role in normal and Alzheimer’s disease states

  2024cites this paper
• Human Platelet Lysate-Derived Nanofibrils as Building Blocks to Produce Free-Standing Membranes for Cell Self-Aggregation

  2024cites this paper
• Quantification of AMPA receptor subunits and RNA editing-related proteins in the J20 mouse model of Alzheimer’s disease by capillary western blotting

  2024cites this paper
• Aβ*56 is present in brain extracts enriched for extracellular proteins

  2024cites this paper
• Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models

  2024cites this paper
• Variation in Group Composition Alters an Early-Stage Social Phenotype in hAPP-Transgenic J20 Mice

  2023cites this paper
• Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease

  2023cites this paper
• Aβ*56 is a stable oligomer that correlates with age-related memory loss in Tg2576 mice

  2023cites this paper
• Human cystatin C induces the disaggregation process of selected amyloid beta peptides: a structural and kinetic view

  2023cites this paper
• The effects of social environment on AD-related pathology in hAPP-J20 mice and tau-P301L mice.

  2023cites this paper
• Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models

  2023cites this paper
• Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease via modulating neuropathology and gut microbiota through suppressing C/EBPβ/AEP pathway

  2023cites this paper
• Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective

  2023cites this paper
• The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer’s disease

  2023cites this paper
• Progressive sleep disturbance in various transgenic mouse models of Alzheimer’s disease

  2023cites this paper
• Goal-Directed Action Is Initially Impaired in a hAPP-J20 Mouse Model of Alzheimer’s Disease

  2023cites this paper
• Whole-body vibration ameliorates glial pathological changes in the hippocampus of hAPP transgenic mice, but does not affect plaque load

  2023cites this paper
• β Bursting in the Retrosplenial Cortex Is a Neurophysiological Correlate of Environmental Novelty Which Is Disrupted in a Mouse Model of Alzheimer's Disease

  2022cites this paper
• Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

  2022cites this paper
• 14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer’s Disease Mouse Models

  2022influential citation
• Alzheimer’s target still viable but untested

  2022cites this paper
• Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease.

  2022cites this paper
• Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches

  2022cites this paper
• Grid cell disruption in a mouse model of early Alzheimer’s disease reflects reduced integration of self-motion cues and increased influence of environmental geometry

  2022cites this paper
• ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease

  2022cites this paper
• Modulation of C5a–C5aR1 signaling alters the dynamics of AD progression

  2022cites this paper
• The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.

  2022cites this paper
• Amyloid-β oligomers in the Nucleus Accumbens Decrease Motivation via Insertion of Calcium-Permeable AMPA Receptors

  2022cites this paper
• Transgenic Mouse Models of Alzheimer’s Disease: An Integrative Analysis

  2022cites this paper
• Adult hippocampal neurogenesis and its impairment in Alzheimer’s disease

  2022cites this paper
• Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer’s-like pathology in mouse and fly APP overexpression models

  2022cites this paper
• Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer’s Disease

  2022cites this paper
• iTRAQ-Based Proteomic Analysis of APP Transgenic Mouse Urine Exosomes

  2022cites this paper
• Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice

  2021cites this paper
• Temporal Lobe Epilepsy and Alzheimer’s Disease: From Preclinical to Clinical Evidence of a Strong Association

  2021cites this paper
• Amyloid Prefibrillar Oligomers: The Surprising Commonalities in Their Structure and Activity

  2021cites this paper
• Phenotypic Differences between the Alzheimer’s Disease-Related hAPP-J20 Model and Heterozygous Zbtb20 Knock-Out Mice

  2021influential citation
• Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

  2021cites this paper
• Sex-specific interactions between procedural and deliberative decision-making systems in a mouse model of Alzheimer’s disease

  2021cites this paper
• mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease

  2021cites this paper
• fvEarly monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

  2021cites this paper
• Machine learning classifies predictive kinematic features in a mouse model of neurodegeneration

  2021cites this paper
• Disruption of the grid cell network in a mouse model of early Alzheimer’s disease

  2021cites this paper
• Reduced Synaptic Transmission and Intrinsic Excitability of a Subtype of Pyramidal Neurons in the Medial Prefrontal Cortex in a Mouse Model of Alzheimer’s Disease

  2021cites this paper
• Distinct types of amyloid‐β oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease

  2021cites this paper
• β-Turn mimetic synthetic peptides as amyloid-β aggregation inhibitors.

  2020cites this paper
• Amyloidosis is associated with thicker myelin and increased oligodendrogenesis in the adult mouse brain

  2020cites this paper
• Time-Resolved Observation of Evolution of Amyloid-β Oligomer with Temporary Salt Crystals.

  2020cites this paper
• The Toxicity and Polymorphism of β-Amyloid Oligomers

  2020cites this paper
• Neuroprotective Effects of Salidroside in a Mouse Model of Alzheimer’s Disease

  2020cites this paper
• Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging

  2020cites this paper
• Misfolded amyloid-β-42 impairs the endosomal–lysosomal pathway

  2020cites this paper
• Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs.

  2020cites this paper
• Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1

  2020cites this paper
• Protofibril–Fibril Interactions Inhibit Amyloid Fibril Assembly by Obstructing Secondary Nucleation

  2020cites this paper
• Behavioural and psychological symptoms of dementia in mouse models of Alzheimer's disease-related pathology: Running title: BPSD in Alzheimer's disease models.

  2020cites this paper
• Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease.

  2020cites this paper
• The good, the bad, and the opportunities of the complement system in neurodegenerative disease

  2020cites this paper
• A New Synuclein-Transgenic Mouse Model for Early Parkinson’s Reveals Molecular Features of Preclinical Disease

  2020cites this paper
• Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ

  2020cites this paper
• Detection of Amyloid β Oligomers with RNA Aptamers in AppNL-G-F/NL-G-F Mice: A Model of Arctic Alzheimer’s Disease

  2020cites this paper
• Corresponding authors

  2020cites this paper
• An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies.

  2019cites this paper
• Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4–10 Prevents Spatial Learning Decline

  2019cites this paper
• Cellular Functions and Mechanisms of Action of Small Heat Shock Proteins.

  2019cites this paper
• Oxymatrine can attenuate pathological deficits of Alzheimer's disease mice through regulation of neuroinflammation.

  2019cites this paper
• Long-term voluntary wheel running does not alter vascular amyloid burden but reduces neuroinflammation in the Tg-SwDI mouse model of cerebral amyloid angiopathy

  2019cites this paper
• Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives

  2019cites this paper
• Neurophysiological alterations in the nucleus reuniens of a mouse model of Alzheimer’s disease

  2019cites this paper
• Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease

  2019cites this paper
• Misfolded Amyloid β-42 induced impairment of the endo-lysosomal pathway revealed by real-time optical monitoring

  2019cites this paper
• Cellular sequestrases maintain basal Hsp70 capacity ensuring balanced proteostasis

  2019cites this paper
• Presymptomatic Treatment With Andrographolide Improves Brain Metabolic Markers and Cognitive Behavior in a Model of Early-Onset Alzheimer’s Disease

  2019cites this paper
• Ion mobility spectrometry combined with multivariate statistical analysis: revealing the effects of a drug candidate for Alzheimer’s disease on Aβ1-40 peptide early assembly

  2019cites this paper
• Looking at the Disordered Proteins through the Computational Microscope

  2018cites this paper
• The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases.

  2018cites this paper
• The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

  2018cites this paper
• Transcription factor NRF2 regulates the expression of autophagy genes

  2018cites this paper
• Inhibiting and Remodeling Toxic Amyloid-Beta Oligomer Formation Using a Computationally Designed Drug Molecule That Targets Alzheimer’s Disease

  2018cites this paper
• Abeta42 oligomers trigger synaptic loss through AMPK-dependent activation of mitochondrial fission and mitophagy

  2018cites this paper
• Formation of Heterotypic Amyloids: α‐Synuclein in Co‐Aggregation

  2018cites this paper
• Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy

  2018cites this paper
• Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease

  2018cites this paper
• The Time Course of Recognition Memory Impairment and Glial Pathology in the hAPP-J20 Mouse Model of Alzheimer’s Disease

  2018cites this paper
• Novel Quantitative Analyses of Spontaneous Synaptic Events in Cortical Pyramidal Cells Reveal Subtle Parvalbumin-Expressing Interneuron Dysfunction in a Knock-In Mouse Model of Alzheimer’s Disease

  2018cites this paper
• Heat-Induced Aggregation of Hen Ovalbumin Suggests a Key Factor Responsible for Serpin Polymerization.

  2018cites this paper
• A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers

  2018cites this paper
• Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons

  2018cites this paper
• Repeat Mild Traumatic Brain Injury in Adolescent Rats Increases Subsequent β-Amyloid Pathogenesis

  2018cites this paper